Valerio Therapeutics

Valerio Therapeutics Société anonyme is a clinical-stage biotechnology company that develops technology platforms for the targeted delivery of therapies. Its platforms include PlatON, a proprietary chemical platform for DNA decoy therapies; DecoyTAC, which couples the mechanism of action of DNA decoy therapies with targeted protein degradation; and the V-body platform, which covers bispecific T-cell engagers, antibody-drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Incorporated in 1997, it is headquartered in Paris, France.